MiR-205 Reverses MDR-1 Mediated Doxorubicin Resistance Via PTEN In Human Liver Cancer HepG2 Cells

Document Type : Original Article


1 Department of Minimally Invasive Intervention, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China

2 Department of Oncology, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China

3 Department of Infectious Diseases, The First Hospital of Yulin, Yulin, Shaanxi, China


Objective: The aim of the recent study was to investigate the effects of miR-205 on reversing Doxorubicin (DOX) resistance, as chemotherapeutic agents through up-regulation of PTEN in human liver cancer HepG2 cells.
Materials and Methods: In this experimental study, the drug resistance in liver cancer cells via drug efflux inhibition and enhancing apoptosis by the regulation of PTEN and multi-drug resistance/ P-glycoprotein (MDR/P-gp) expression was revealed. Using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, effect of DOX on cell proliferation was evaluated after miR-205 transfection in HepG2 and HepG2/DOX cells. Activity of P-gp on drug efflux was measured by the Rhodamine 123 (Rho-123) assay. PTEN mRNA expression levels were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and flow cytometry was used to measure the apoptotic ratio of HepG2/DOX cells.
Results: miR-205 overexpression considerably inhibited the HepG2/DOX cells viability (P<0.05). qRT-PCR results revealed that PTEN is a pivotal regulator in PI3K/Akt/P-gp axis. Overexpression miR-205 resulted in up-regulation PTEN and ultimately down-regulation of P-gp. This inhibits drug resistance, proliferation and induces apoptosis in HepG2/DOX cells (P<0.05). Whilst, treatment with 10 μM of special inhibitors, including LY294002 (PI3K) or PD098059 (MAPK), increased Rho 123-associated MFI, treatment with 10 μM of SF1670 (PTEN) almost abolished the effect of miR-205 overexpression (P<0.05). Finally, we found that miR-205 was down-regulated in HepG2/DOX cells, and its overexpression led to enhancing apoptosis with re-sensitization of HepG2/DOX cell lines to DOX through PTEN/PI3K/ Akt/MDR1 pathway.
Conclusion: These findings may introduce miR-205 as a predictive biomarker and a potential treatment target for liver cancer therapy during MDR. 


  1. Chai Z, Yin X, Chen J, Shi J, Sun J, Liu C, et al. MicroRNA‑101 modulates cisplatin chemoresistance in liver cancer cells via the DNA‑PKcs signaling pathway. Oncol Lett. 2019; 18(4): 3655-3663.
  2. Pan C, Wang X, Shi K, Zheng Y, Li J, Chen Y, et al. MiR-122 reverses the doxorubicin-resistance in hepatocellular carcinoma cells through regulating the tumor metabolism. PLoS One. 2016; 11(5): e0152090.
  3. Donato MT, Tolosa L,Gomez-Lechon MJ. Culture and functional characterization of human hepatoma HepG2 cells. Methods Mol Biol. 2015; 1250: 77-93.
  4. Harjumäki R, Nugroho RWN, Zhang X, Lou YR, Yliperttula M, Valle-Delgado JJ, et al. Quantified forces between HepG2 hepato carcinoma and WA07 pluripotent stem cells with natural biomaterials correlate with in vitro cell behavior. Sci Rep. 2019; 9(1): 7354.
  5. Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 2017; 48(2): 103-114.
  6. Lage H, Aki-Sener E, Yalcin I. High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs. Int J Cancer. 2006; 119(1): 213-220.
  7. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009; 9(5): 338-350.
  8. Xu F, Wang F, Yang T, Sheng Y, Zhong T, Chen Y. Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell Int. 2014; 14(1): 142.
  9. Katayama K, Noguchi K, Sugimoto Y. Regulations of P-glycoprotein/ ABCB1/MDR1 in human cancer cells. New J Sci. 2014; 2014.
  10. Yousefi B, Samadi N, Baradaran B, Rameshknia V, Shafiei-Irannejad V, Majidinia M, et al. Differential effects of peroxisome proliferator- activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Cell Mol Biol (Noisy-legrand). 2015; 61(8): 118-122.
  11. Zhang J, Gu Y, Chen B. Mechanisms of drug resistance in acute myeloid leukemia. Onco Targets Ther. 2019; 12: 1937-1945.
  12. Yousefi B, Azimi A, Majidinia M, Shafiei-Irannejad V, Badalzadeh R, Baradaran B, et al. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ- dependent manner in leukemia cells. Tumour Biol. 2017; 39(10): 1010428317716501.
  13. Nanayakkara AK, Follit CA, Chen G, Williams NS, Vogel PD, Wise JG. Targeted inhibitors of P-glycoprotein increase chemotherapeutic- induced mortality of multidrug resistant tumor cells. Sci Rep. 2018; 8(1): 967.
  14. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005; 117(3): 376-380.
  15. Yousefi B, Samadi N, Ahmadi Y. Akt and p53R2, partners that dictate the progression and invasiveness of cancer. DNA Repair (Amst). 2014; 22: 24-29.
  16. Joshi P, Vishwakarma RA, Bharate SB. Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer. Eur J Med Chem. 2017; 138: 273-292.
  17. Longley DB,Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2): 275-292.
  18. Wang J, Chan JYW, Fong CC, Tzang CH, Fung KP,Yang M. Transcriptional analysis of doxorubicin‐induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines. Liver Int. 2009; 29(9): 1338-1347.
  19. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV Infection by Targeting Micro- RNA. N Engl J Med. 2013; 368(18): 1685-1694.
  20. Hu Y, Qiu Y, Yagüe E, Ji W, Liu J, Zhang J. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis. 2016; 7(6): e2291.
  21. Li J, Hu K, Gong G, Zhu D, Wang Y, Liu H, et al. Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Rep. 2017; 7: 41330.
  22. Zhao Y, Chen J, Wei W, Qi X, Li C, Ren J. The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma. Signal Transduct Target Ther. 2018; 3: 3.
  23. Berindan-Neagoe I, Monroig PdC, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014; 64(5): 311-336.
  24. Ma C, Shi X, Guo W, Feng F, Wang G. miR‑205‑5p downregulation decreases gemcitabine sensitivity of breast cancer cells via ERp29 upregulation. Exp Ther Med. 2019; 18(5): 3525-3533.
  25. Zhu L, Liu R, Zhang W, Qian S,Wang JH. MicroRNA-205 regulates ubiquitin specific peptidase 7 protein expression in hepatocellular carcinoma cells. Mol Med Rep. 2015; 12(3): 4652-4656.
  26. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365(12): 1118-1127.
  27. To KKW. MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J Biomed Sci. 2013; 20(1): 99.
  28. Nordby Y, Richardsen E, Ness N, Donnem T, Patel HRH, Busund LT, et al. High miR-205 expression in normal epithelium is associated with biochemical failure-an argument for epithelial crosstalk in prostate cancer? Sci Rep. 2017; 7(1): 16308.
  29. Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, et al. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 2013; 73(17): 5402-5415.
  30. Hezova R, Kovarikova A, Srovnal J, Zemanova M, Harustiak T, Ehrmann J, et al. MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus. Tumour Biol. 2016; 37(6): 8007-8018.
  31. Shao P, Qu WK, Wang CY, Tian Y, Ye ML, Sun DG, et al. MicroRNA- 205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway. Am J Transl Res. 2017; 9(9): 4300-4307.
  32. Bai J, Zhu X, Ma J, Wang W. miR-205 regulates A549 cells proliferation by targeting PTEN. Int J Clin Exp Pathol.2015; 8(2): 1175- 1183.
  33. Bhatnagar N, Li X, Padi SKR, Zhang Q, Tang MS, Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy- induced apoptosis in prostate cancer cells. Cell Death Dis. 2010; 1(12): e105.
  34. Chaudhary AK, Mondal G, Kumar V, Kattel K, Mahato RI. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Cancer Lett. 2017; 402: 1-8.
  35. Qu C, Liang Z, Huang J, Zhao R, Su C, Wang S, et al. MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle. 2012; 11(4): 785-796.
  36. Chen JR, Jia XH, Wang H, Yi YJ, Wang JY, Li YJ. Timosaponin AIII reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. Int J Oncol. 2016; 48(5): 2063-2070.
  37. Shi X, Xiao L, Mao X, He J, Ding Y, Huang J, et al. miR-205-5p mediated downregulation of PTEN contributes to cisplatin resistance in C13K human ovarian cancer cells. Front Genet. 2018; 9: 555.
  38. Sun W, Ma Y, Chen P, Wang D. MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-beta/Smad2/STAT3/STAT5 pathway. Mol Med Rep. 2015; 11(5): 3854-3859.
  39. Haenisch S, Werk AN, Cascorbi I. MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol. 2014; 77(4): 587-596.
  40. Zheng SZ, Sun P, Wang JP, Liu Y, Gong W, Liu J. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells. World J Gastroenterol. 2019; 25(22): 2752-2762.